首页/数据集/TBCRC 001: Randomized Phase II Study of Cetuximab in Combination with Carboplatin in Stage IV Triple Negative Breast Cancer

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination with Carboplatin in Stage IV Triple Negative Breast Cancer

ChEBI2012-07-13 更新2026-07-21 收录

癌症临床试验

三阴性乳腺癌治疗

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-23428 数据链接链接失效反馈

官方服务：

资源简介：

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination with Carboplatin in Stage IV Triple Negative Breast Cancer

应用场景：

创建时间：

2012-07-13

三阴性乳腺癌治疗

药物靶点发现

Resveratrol (RSV) is known to possess anticancer properties in many types of cancers like breast cancer, in which POLD1 may serve as a potential target. However, the anticancer mechanism of RSV on tri

NIAID Data Ecosystem70

A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy

三阴性乳腺癌治疗

自噬调控

Patients with triple-negative breast cancer (TNBC) often have a poor prognosis largely due to lack of effective targeted therapy. Using a library of seleno-purines coupled to a high-throughput biochem

NIAID Data Ecosystem50

Withdrawal of Consent in The Critical Illness Stress-induced Immune Suppression Prevention Trial

重症儿童医疗

癌症临床试验

Withdrawal of Consent Study Description Despite strict hand washing, sterile technique, and antibiotic-coated catheters, nosocomial infection and sepsis remain the leading acquired causes of morbidity

NIAID Data Ecosystem30

Cytochalasin D as a potential MAPK family inhibitor for treating triple-negative breast cancer

三阴性乳腺癌治疗

MAPK信号通路

Cytochalasin D, a potent fungal metabolite, has garnered considerable attention due to its diverse biological activities and potential pharmacological applications. Renowned for its ability to disrupt

Taylor & Francis Group2025-02-27 更新50

Human TNBC Cells 72h Treatment with 4.5nM OTSSP167 MELK Inhibitor vs. DMSO Control (SUM159). Homo sapiens

三阴性乳腺癌治疗

MEK抑制剂机制

Microarray comparing TNBC cells treated for 72 hours with OTSSP167 MELK Inhibitor and control (DMSO) Overall design: Two-condition arrays: SUM159 cells were treated with either 4.5nM OTSSP167 MELK Inh

NIAID Data Ecosystem40

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination with Carboplatin in Stage IV Triple Negative Breast Cancer

资源简介：

相关数据集